{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:31:02Z","timestamp":1792161062237,"version":"4.4.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.intimp.2020.106455","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T04:29:33Z","timestamp":1585801773000},"page":"106455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":105,"special_numbering":"C","title":["The possible of immunotherapy for COVID-19: A systematic review"],"prefix":"10.1016","volume":"83","author":[{"given":"Akram","family":"AminJafari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9986-4930","authenticated-orcid":false,"given":"Sorayya","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2020.106455_b0005","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens9020148","article-title":"Emergence of novel coronavirus 2019-nCoV: need for rapid vaccine and biologics development","volume":"9","author":"Shanmugaraj","year":"2020","journal-title":"Pathogens"},{"issue":"1","key":"10.1016\/j.intimp.2020.106455_b0010","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/01652176.2020.1727993","article-title":"Emerging novel coronavirus (2019-nCoV)\u2014current scenario, evolutionary perspective based on genome analysis and recent developments","volume":"40","author":"Malik","year":"2020","journal-title":"Veterinary Quart."},{"key":"10.1016\/j.intimp.2020.106455_b0015","article-title":"Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)","author":"Shanmugaraj","year":"2020","journal-title":"Asian Pac. J. Allergy Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2020.106455_b0020","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9030623","article-title":"Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review","volume":"9","author":"Pang","year":"2020","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.intimp.2020.106455_b0025","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody","volume":"9","author":"Tian","year":"2020","journal-title":"Emerg. Microbes Infect."},{"issue":"4","key":"10.1016\/j.intimp.2020.106455_b0030","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann. Internal Med."},{"key":"10.1016\/j.intimp.2020.106455_b0035","article-title":"Clinical trial analysis of 2019-nCoV therapy registered in China","author":"Zhang","year":"2020","journal-title":"J Med. Virol."},{"key":"10.1016\/j.intimp.2020.106455_b0040","first-page":"1","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","author":"Tai","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2020.106455_b0045","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25698","article-title":"Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV","author":"Baruah","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.intimp.2020.106455_b0050","doi-asserted-by":"crossref","first-page":"72","DOI":"10.12688\/f1000research.22211.2","article-title":"Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China","volume":"9","author":"Kruse","year":"2020","journal-title":"F1000Res"},{"issue":"1781","key":"10.1016\/j.intimp.2020.106455_b0055","article-title":"Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus","volume":"10","author":"Yong","year":"2019","journal-title":"Front. Microbiol"},{"issue":"3","key":"10.1016\/j.intimp.2020.106455_b0060","doi-asserted-by":"crossref","DOI":"10.3390\/v12030254","article-title":"Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies","volume":"12","author":"Ahmed","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.intimp.2020.106455_b0065","doi-asserted-by":"crossref","unstructured":"T. Liu, et al., The potential role of IL-6 in monitoring coronavirus disease, 2019. Available at SSRN 3548761, 2020.","DOI":"10.2139\/ssrn.3548761"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920309127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920309127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:20:56Z","timestamp":1761585656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576920309127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":13,"alternative-id":["S1567576920309127"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106455","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The possible of immunotherapy for COVID-19: A systematic review","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106455","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106455"}}